3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
"3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21)
Descriptor ID |
D019900
|
MeSH Number(s) |
D03.383.773.170
|
Concept/Terms |
U-50488- U-50488
- U 50488
- U50488
- U-50488H
- U 50488H
- U50488H
- U-50,488H
- U 50,488H
- U50,488H
|
Below are MeSH descriptors whose meaning is more general than "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer".
Below are MeSH descriptors whose meaning is more specific than "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer".
This graph shows the total number of publications written about "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" by people in this website by year, and whether "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
1999 | 1 | 1 | 2 |
2010 | 0 | 2 | 2 |
2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" by people in Profiles.
-
Taylor AM, Roberts KW, Pradhan AA, Akbari HA, Walwyn W, Lutfy K, Carroll FI, Cahill CM, Evans CJ. Anti-nociception mediated by a ? opioid receptor agonist is blocked by a d receptor agonist. Br J Pharmacol. 2015 Jan; 172(2):691-703.
-
Lawson KP, Nag S, Thompson AD, Mokha SS. Sex-specificity and estrogen-dependence of kappa opioid receptor-mediated antinociception and antihyperalgesia. Pain. 2010 Dec; 151(3):806-815.
-
Vel?zquez-Marrero CM, Marrero HG, Lemos JR. Voltage-dependent kappa-opioid modulation of action potential waveform-elicited calcium currents in neurohypophysial terminals. J Cell Physiol. 2010 Oct; 225(1):223-32.
-
Lutfy K, Doan P, Nguyen M, Weber E. Effects of ACEA-1328, a NMDA receptor/glycine site antagonist, on U50,488H-induced antinociception and tolerance. Eur J Pharmacol. 1999 Nov 12; 384(1):1-5.
-
Wang XM, Zhang KM, Long LO, Mokha SS. Orphanin FQ (nociceptin) modulates responses of trigeminal neurons evoked by excitatory amino acids and somatosensory stimuli, and blocks the substance P-induced facilitation of N-methyl-D-aspartate-evoked responses. Neuroscience. 1999; 93(2):703-12.
-
Lutfy K, Doan P, Nugyen M, Weber E. ACEA-1328, an NMDA receptor antagonist, increases the potency of morphine and U50,488H in the tail flick test in mice. Pharmacol Res. 1998 Dec; 38(6):453-60.